Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- and ribavirin-free regimens

Journal of the American Geriatrics Society

Volumn 64, Issue 2, 2016, Pages 386-393

  Younossi, Zobair M ^a   Stepanova, Maria ^b   Nader, Fatema ^a,c   Henry, Linda ^b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Center for Outcomes Research in Liver Diseases   (United States)

^c BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

chronic hepatitis C; CLDQ HCV; health related quality of life; LDV SOF; older adults; WPAI:SHP

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; INTERFERON; LEDIPASVIR;

AGED; ARTICLE; CHRONIC HEPATITIS C; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIVARIATE ANALYSIS; PATIENT REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RATING SCALE; SELF REPORT; TREATMENT OUTCOME; VIRAL CLEARANCE; CLINICAL TRIAL; HEPATITIS C, CHRONIC; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME;

EID: 84958870076     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/jgs.13928     Document Type: Article

References (40)

1. Hope VD, Eramova I, Capurro D, et al., Prevalence and estimation of hepatitis B and C infections in the WHO European Region: A review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014; 142: 270-286.
2. Kharyriyyah MH, Groeger J, Flaxman AD, et al., Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatol 2013; 57: 1333-1342.
3. Davis GL, Alter MJ, El-Serag H, et al., Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression. Gastroenterol 2010; 138: 513-521.
4. Gordon SC, Pockros PJ, Terrault NA, et al., Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-1660.
5. Gramenzi A, Conti F, Felline F, et al., Hepatitis C Virus-related chronic liver disease in elderly patients: An Italian cross-sectional study. J Viral Hepat 2009; 17: 360-366.
6. Younossi ZM, Stepanova M, Mishra A, et al., The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther 2013; 38: 1065-1075.
7. McHutchison JG, Ware JE, Bayliss MS, et al., The effects of interferon alpha 2-b in combination with ribavirin and health related quality of life and productivity. J Hepatol 2001; 34: 140-147.
8. Razavi H, Elkhoury AC, Elbasha E, et al., Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-2170.
9. Davis GL, Albright JE, Cook SF, et al., Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
10. Sobhonslidsuk A, Silpakit C, Kongsakon R, et al., Factors influencing health-related quality of life in chronic liver disease. World J Gastroenterol 2006; 12: 7786-7791.
11. Gutteling JJ, de Man RA, van der Plas SM, et al., Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther 2006; 23: 1629-1635.
12. Hassoun Z, Willems B, Deslauriers J, et al., Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale. Dig Dis Sci 2002; 47: 2674-2681.
13. Kallman J, O'Neil MM, Larive B, et al., Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-2539.
14. Loria A, Doyle K, Weinstein AA, et al., Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil. 2014; 93: 470-6.
15. Younossi ZM,. Chronic liver disease and health-related quality of life. Gastroenterology 2001; 120: 305-307.
16. Afendy A1, Kallman JB, Stepanova M, et al., Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-476.
17. Gutteling JJ, Duivenvoorden HJ, Busschbach JJ, et al., Psychological determinants of health-related quality of life in patients with chronic liver disease. Psychosomatics. 2010; 51: 157-165.
18. Smith BD, Morgan RL, Beckett GA, et al., Recommendations for the identification of chronic hepatitis C Virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 4: 1-32.
19. Smith BD, Morgan RL, Beckett GA, et al., Hepatitis C Virus testing of persons born during 1945-1965: Recommendations from the centers for disease control and prevention. Ann Intern Med 2012; 157: 817-822.
20. Lawitz E, Mangia A, Wyles D, et al., Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887.
21. Younossi ZM, Singer ME, Mir HM, et al., Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-537.
22. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM,. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015; 8: 298-312.
23. Jacobson IM, Gordon SC, Kowdley KV, et al.,; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877.
24. Afdhal N, Zeuzem S, Kwo P, et al.,; ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898.
25. Afdhal N, Reddy KR, Nelson DR, et al.,; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493.
26. Zeuzem S, Dusheiko GM, Salupere R, et al.,; VALENCE Investigators. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001.
27. Kowdley KV, Gordon SC, Reddy KR, et al.,; ION-3 Investigators. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888.
28. Zeuzem S, Dusheiko G, Salupere R, et al., Sofosbuvir+Ribavirin for 12 or 24 Weeks for Patients with HCV Genotype 2 or 3: The VALENCE trial. Hepatology 2013; 58: 1085.
29. Ware JE, Kosinski M,. Interpreting SF-36 summary health measures: A response. Qual Life Res 2001; 10: 405-413.
30. Webster K, Odom L, Peterman A, et al., The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: Validation of version 4 of the core questionnaire. Qual Life Res 1999; 8: 604.
31. Younossi ZM, Guyatt G, Kiwi M, et al., Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999; 45: 295-300.
32. Reilly MC, Zbrozek AS, Dukes EM,. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.
33. Stepanova M, Nader F, Cure S, et al., Patients' preferences and health utility assessment with SF-6D and EQ-5D in patients with chronic hepatitis C treated with sofosbuvir regimens. Aliment Pharmacol Ther. 2014; 40: 676-85.
34. Younossi ZM, Stepanova M, Henry L, et al., Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014; 12: 1349-5.
35. Younossi ZM, Stepanova M, Nader F, et al., Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology 2014; 59: 2161-2169.
36. Younossi ZM, Stepanova M, Zeuzem S, et al., Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE Study. J Hepatol. 2014; 61: 228-34.
37. Younossi ZM, Stepanova M, Marcellin P, et al., Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology. 2015; 61: 1798-808.
38. Otgonsuren M, Henry L, Hunt S, et al., Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci 2015; 60: 320-332.
39. Davis GL, Roberts WL,. The healthcare burden imposed by liver disease in aging Baby Boomers. Curr Gastroenterol Rep 2010; 12: 1-6.
40. Food and Drug Administration- Hepatitis B and C treatments. Obtained from the world wide web at http://www.fda.gov/ForPatients/Illness/HepatitisBC/ucm408658.htm. Last accessed on 5 Dec 2015.